

# CATHETER PERINERVEUX

Quelles indications en 2021 ?

Axel Maurice-Szamburski

M.D., Anesthésie Réanimation, Clinique Juge

Ph.D., Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de Vie

# Réactualisation de la recommandation sur la douleur postopératoire<sup>☆</sup>


Frédéric Aubrun<sup>1</sup>, Karine Nouette Gaulain<sup>2</sup>, Dominique Fletcher<sup>3</sup>, Anissa Belbachir<sup>4</sup>,  
Hélène Beloeil<sup>5</sup>, Michel Carles<sup>6</sup>, Philippe Cuvillon<sup>7</sup>, Christophe Dadure<sup>8</sup>, Gilles Lebuffe<sup>9</sup>,  
Emmanuel Marret<sup>10</sup>, Valéria Martinez<sup>3</sup>, Michel Olivier<sup>11</sup>, Nadia Sabourdin<sup>12</sup>, Paul Zetlaoui<sup>13</sup>,  
Société française d'anesthésie et de réanimation

**Recommandations formalisées d'experts**

Argumentaire : la littérature récente confirme l'intérêt d'un cathéter périmerveux en cas de risque de douleur postopératoire modérée à sévère en particulier dans la chirurgie prothétique de l'épaule (interscalénique) et du genou (fémoral) [60,61]. Outre l'efficacité analgésique prolongée, le bénéfice porte sur l'épargne opioïde et la réduction des effets adverses morphiniques (NVPO), sur l'amélioration du sommeil et la satisfaction des patients.


## Using postoperative pain trajectories to define the role of regional analgesia in personalised pain medicine

E. R. Mariano,<sup>1,2</sup> K. El-Boghdadly<sup>3,4</sup> and B. M. Ilfeld<sup>5,6</sup>




# Using postoperative pain trajectories to define the role of regional analgesia in personalised pain medicine

E. R. Mariano,<sup>1,2</sup> K. El-Boghdadly<sup>3,4</sup> and B. M. Ilfeld<sup>5,6</sup>




## Using postoperative pain trajectories to define the role of regional analgesia in personalised pain medicine



E. R. Mariano,<sup>1,2</sup> K. El-Boghdadly<sup>3,4</sup> and B. M. Ilfeld<sup>5,6</sup>



## Using postoperative pain trajectories to define the role of regional analgesia in personalised pain medicine

E. R. Mariano,<sup>1,2</sup> K. El-Boghdadly<sup>3,4</sup> and B. M. Ilfeld<sup>5,6</sup>





# Somatic and Psychologic Predictors of Long-term Unfavorable Outcome After Surgical Intervention


*Madelon L. Peters, PhD,\* Micha Sommer, MD,† Janneke M. de Rijke, PhD,†*

**TABLE 2.** The Association of Step 3 and 4 Predictor Variables With Outcome Variables Increased Pain at 6-Month Follow-up, Increased Functional Limitations at 6-Month Follow-up and Poor Global Recovery

Independent Variable	n	Increased Pain at Follow-up		Increased Functional Limitations at Follow-up		Poor Global Recovery	
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Preop. pain							
No	274	1.00		1.00		1.00	
Yes	351	0.32 (0.17–0.60)	0.001	NE		1.90 (1.21–2.97)	0.01
Duration of surgery							
<3 hr	545	1.00		1.00		1.00	
≥3 hr	80	2.00 (1.01–3.97)	0.05	4.24 (2.33–7.71)	0.001	2.45 (1.37–4.39)	0.01
Pain on day 4							
Pain <40	551	1.00		1.00		1.00	
Pain ≥40	74	3.21 (1.64–6.30)	0.001	1.87 (1.02–3.41)	0.04	2.61 (1.47–4.62)	0.001
ASA status							
ASA grade I	262	1.00		1.00		1.00	
ASA grade II	274	NE		1.38 (0.80–2.38)	0.24	NE	
ASA grade III	89	NE		2.40 (1.17–4.90)	0.02	NE	
Long-term fear							
Low (<10)	304	1.00		1.00		1.00	
High (≥10)	321	1.90 (1.08–3.33)	0.03	NE		1.98 (1.34–2.94)	0.001
Optimism							
Low (<28)	292	1.00		1.00		1.00	
High (≥28)	333	NE		NE		0.60 (0.41–0.87)	0.01


# Perineural Versus Systemic Dexamethasone in Front-Foot Surgery Under Ankle Block: A Randomized Double-Blind Study

Philippe Marty, MD \*, Olivier Rontes, MD \*, Clément Chassery, MD \*, Corine Vuillaume, MD \*, Bertrand Basset, MD \*




# Perineural Versus Systemic Dexamethasone in Front-Foot Surgery Under Ankle Block: A Randomized Double-Blind Study

Philippe Marty, MD \*, Olivier Rontes, MD \*, Clément Chassery, MD \*, Corine Vuillaume, MD \*, Bertrand Basset, MD \*




# Ultrasound-Guided Motor-Sparing Knee Blocks for Postoperative Analgesia Following Total Knee Arthroplasty

Olawale A. Sogbein, MES, MSc, Rakesh V. Sondekoppam, MBBS, MD, Dianne Bryant, PhD




# Ultrasound-Guided Motor-Sparing Knee Blocks for Postoperative Analgesia Following Total Knee Arthroplasty

Olawale A. Sogbein, MES, MSc, Rakesh V. Sondekoppam, MBBS, MD, Dianne Bryant, PhD




# Should continuous rather than single-injection interscalene block be routinely offered for major shoulder surgery? A meta-analysis of the analgesic and side-effects profiles

L. Vorobeichik<sup>1</sup>, R. Brull<sup>1,2</sup>, R. Bowry<sup>1,3</sup>, J. G. Laffey<sup>1,4,5,6</sup> and F. W. Abdallah<sup>1,4,5,7</sup>




# Should continuous rather than single-injection interscalene block be routinely offered for major shoulder surgery? A meta-analysis of the analgesic and side-effects profiles

L. Vorobeichik<sup>1</sup>, R. Brull<sup>1,2</sup>, R. Bowry<sup>1,3</sup>, J. G. Laffey<sup>1,4,5,6</sup> and F. W. Abdallah<sup>1,4,5,7</sup>



# Association of Early Postoperative Pain Trajectories With Longer-term Pain Outcome After Primary Total Knee Arthroplasty

Jasvinder A. Singh, MBBS, MPH; Celeste A. Lemay, RN, MPH; Lisa Nobel, PhD; Wenyun Yang, MS; Norman Weissman, MD, MPH; Kenneth



# Association of Early Postoperative Pain Trajectories With Longer-term Pain Outcome After Primary Total Knee Arthroplasty

Jasvinder A. Singh, MBBS, MPH; Celeste A. Lemay, RN, MPH; Lisa Nobel, PhD; Wenyun Yang, MS; Norman Weissman, MD, MPH; Kenneth



**Table 2. Multivariable-Adjusted Logistic Regression Model Assessing Pre-Total Knee Arthroplasty (TKA) Factors Associated With the Slow Pain Responder Trajectory<sup>a</sup>**

Variable	Full Model <sup>b</sup>	
	OR (95% CI)	P Value
Preoperative SF-36 MCS score, with 1-unit increase	0.98 (0.96-1.00)	.02
Preoperative KOOS activities of daily living score for surgical knee, with 1-unit increase	0.97 (0.95-0.99)	.007

# Association of Early Postoperative Pain Trajectories With Longer-term Pain Outcome After Primary Total Knee Arthroplasty

Jasvinder A. Singh, MBBS, MPH; Celeste A. Lemay, RN, MPH; Lisa Nobel, PhD; Wenyun Yang, MS; Norman Weissman, MD, MPH; Kenneth

**Table 2. Multivariable-Adjusted Logistic Regression Model Assessing Pre-Total Knee Arthroplasty (TKA) Factors Associated With the Slow Pain Responder Trajectory<sup>a</sup>**

Variable	Full Model <sup>b</sup>	
	OR (95% CI)	P Value
Preoperative SF-36 MCS score, with 1-unit increase	0.98 (0.96-1.00)	.02
Preoperative KOOS activities of daily living score for surgical knee, with 1-unit increase	0.97 (0.95-0.99)	.007

# Patient and Procedural Determinants of Postoperative Pain Trajectories

Terrie Vasilopoulos, Ph.D.; Richa Wardhan, M.D.; Parisa Rashidi, Ph.D.; Roger B. Fillingim, Ph.D.; Margaret R. Wallace, Ph.D.; Paul L. Crispen, M.D.; Hari K. Parvataneni, M.D.; Hernan A. Prieto, M.D.; Tiago N. Machuca, M.D., Ph.D.; Steven J. Hughes, M.D.

Patient Demographics	Odds Ratio (95% CI)		
	Moderate-to-Low Bootstrapped	Moderate-to-High Bootstrapped	High Bootstrapped
Age, yr	0.97 (0.93, 1.02)	0.96 (0.93, 1.00)	<b>0.94 (0.91, 0.99)</b>
Sex (Ref: male)			
Female	2.49 (0.91, 6.3)	<b>3.52 (1.40, 8.5)</b>	<b>6.4 (1.49, 15.6)</b>
Patient-Reported Outcomes Measurement Information System Anxiety	1.00 (0.95, 1.04)	1.02 (0.98, 1.08)	<b>1.08 (1.01, 1.14)</b>
Patient-Reported Outcomes Measurement Information System Pain Behavior	1.03 (0.98, 1.09)	1.04 (0.99, 1.08)	<b>1.10 (1.02, 1.18)</b>
Pain Catastrophizing Scale	1.00 (0.94, 1.06)	1.03 (0.98, 1.09)	1.01 (0.95, 1.08)
Intraoperative opioids (oral morphine milligram equivalents)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	1.01 (1.00, 1.01)
Intraoperative ketamine, mg	0.99 (0.97, 1.02)	1.01 (0.99, 1.02)	1.00 (0.98, 1.03)
Intraoperative lidocaine, mg	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	0.99 (0.98, 1.01)
Surgical service (Ref: colorectal and urology surgery)			
Orthopedics and spine	1.21 (0.318, 4.3)	1.30 (0.316, 4.8)	2.38 (0.46, 8.7)
Pancreas, biliary, and transplant	0.63 (0.171, 4.9)	1.80 (0.56, 8.7)	4.2 (0.91, 21.0)
Thoracic	1.55 (0.359, 5.5)	2.38 (0.71, 9.1)	1.96 (0.261, 9.0)

# Patient and Procedural Determinants of Postoperative Pain Trajectories

Terrie Vasilopoulos, Ph.D.; Richa Wardhan, M.D.; Parisa Rashidi, Ph.D.; Roger B. Fillingim, Ph.D.; Margaret R. Wallace, Ph.D.; Paul L. Crispen, M.D.; Hari K. Parvataneni, M.D.; Hernan A. Prieto, M.D.; Tiago N. Machuca, M.D., Ph.D.; Steven J. Hughes, M.D.

Patient Demographics	Odds Ratio (95% CI)		
	Moderate-to-Low Bootstrapped	Moderate-to-High Bootstrapped	High Bootstrapped
Age, yr	0.97 (0.93, 1.02)	0.96 (0.93, 1.00)	<b>0.94 (0.91, 0.99)</b>
Sex (Ref: male)			
Female	2.49 (0.91, 6.3)	<b>3.52 (1.40, 8.5)</b>	<b>6.4 (1.49, 15.6)</b>
Patient-Reported Outcomes Measurement Information System Anxiety	1.00 (0.95, 1.04)	1.02 (0.98, 1.08)	<b>1.08 (1.01, 1.14)</b>
Patient-Reported Outcomes Measurement Information System Pain Behavior	1.03 (0.98, 1.09)	1.04 (0.99, 1.08)	<b>1.10 (1.02, 1.18)</b>
Pain Catastrophizing Scale	1.00 (0.94, 1.06)	1.03 (0.98, 1.09)	1.01 (0.95, 1.08)
Intraoperative opioids (oral morphine milligram equivalents)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	1.01 (1.00, 1.01)
Intraoperative ketamine, mg	0.99 (0.97, 1.02)	1.01 (0.99, 1.02)	1.00 (0.98, 1.03)
Intraoperative lidocaine, mg	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	0.99 (0.98, 1.01)
Surgical service (Ref: colorectal and urology surgery)			
Orthopedics and spine	1.21 (0.318, 4.3)	1.30 (0.316, 4.8)	2.38 (0.46, 8.7)
Pancreas, biliary, and transplant	0.63 (0.171, 4.9)	1.80 (0.56, 8.7)	4.2 (0.91, 21.0)
Thoracic	1.55 (0.359, 5.5)	2.38 (0.71, 9.1)	1.96 (0.261, 9.0)

# Patients' pre-operative general and specific outcome expectations predict postoperative pain and function after total knee and total hip arthroplasties

Claire Tilbury\*, Tsjitske M. Haanstra, Suzan H.M. Verdegaal, Rob G.H.H. Nelissen,

SCANDINAVIAN  
JOURNAL OF  
PAIN

## Final prediction model for the outcome pain [general outcome expectations (CEQ)]

Variable	B	p-Value	95% CI
BMI	-1.00	0.00	-1.63; -0.38
Mental health	0.42	0.04	0.14; 0.71
Outcome expectations (CEQ expectancy)	0.80	0.09	-0.11; 1.72

R<sup>2</sup> for the final model: 0.170

## Final prediction model for the outcome pain in which the general outcome expectations (CEQ) score was included

Variable	B	p-Value	95% CI
Baseline function (HOOS ADL)	0.33	0.00	0.172; 0.0477
Kellgren and Lawrence score	3.72	0.090	-0.592; 8.021
Outcome expectations (CEQ expectancy)	0.98	0.049	0.004; 1.958

R<sup>2</sup> for the final model: 0.184

# Patients' pre-operative general and specific outcome expectations predict postoperative pain and function after total knee and total hip arthroplasties

Claire Tilbury\*, Tsjitske M. Haanstra, Suzan H.M. Verdegaal, Rob G.H.H. Nelissen,

SCANDINAVIAN  
JOURNAL OF  
PAIN

## Final prediction model for the outcome pain [general outcome expectations (CEQ)]

Variable	B	p-Value	95% CI
BMI	-1.00	0.00	-1.63; -0.38
Mental health	0.42	0.04	0.14; 0.71
Outcome expectations (CEQ expectancy)	0.80	0.09	-0.11; 1.72

R<sup>2</sup> for the final model: 0.170

## Final prediction model for the outcome pain in which the general outcome expectations (CEQ) score was included

Variable	B	p-Value	95% CI
Baseline function (HOOS ADL)	0.33	0.00	0.172; 0.0477
Kellgren and Lawrence score	3.72	0.090	-0.592; 8.021
Outcome expectations (CEQ expectancy)	0.98	0.049	0.004; 1.958

R<sup>2</sup> for the final model: 0.184

# Patients' pre-operative general and specific outcome expectations predict postoperative pain and function after total knee and total hip arthroplasties

Claire Tilbury\*, Tsjitske M. Haanstra, Suzan H.M. Verdegaal, Rob G.H.H. Nelissen,

SCANDINAVIAN  
JOURNAL OF  
PAIN

## Final prediction model for the outcome pain [general outcome expectations (CEQ)]

Variable	B	p-Value	95% CI
BMI	-1.00	0.00	-1.63; -0.38
Mental health	0.42	0.04	0.14; 0.71
Outcome expectations (CEQ expectancy)	0.80	0.09	-0.11; 1.72

R<sup>2</sup> for the final model: 0.170

## Final prediction model for the outcome pain in which the general outcome expectations (CEQ) score was included

Variable	B	p-Value	95% CI
Baseline function (HOOS ADL)	0.33	0.00	0.172; 0.0477
Kellgren and Lawrence score	3.72	0.090	-0.592; 8.021
Outcome expectations (CEQ expectancy)	0.98	0.049	0.004; 1.958

R<sup>2</sup> for the final model: 0.184

# VULNERABILITE A LA DOULEUR

Facteur chirurgical + Facteur patient

# Réactualisation de la recommandation sur la douleur postopératoire<sup>☆</sup>

Frédéric Aubrun<sup>1</sup>, Karine Nouette Gaulain<sup>2</sup>, Dominique Fletcher<sup>3</sup>, Anissa Belbachir<sup>4</sup>,  
Hélène Beloeil<sup>5</sup>, Michel Carles<sup>6</sup>, Philippe Cuvillon<sup>7</sup>, Christophe Dadure<sup>8</sup>, Gilles Lebuffe<sup>9</sup>,  
Emmanuel Marret<sup>10</sup>, Valéria Martinez<sup>3</sup>, Michel Olivier<sup>11</sup>, Nadia Sabourdin<sup>12</sup>, Paul Zetlaoui<sup>13</sup>,  
Société française d'anesthésie et de réanimation

**Recommandations formalisées d'experts**

Toutefois, les données factuelles ne permettent pas de démontrer l'apport des cathéters périmerveux sur la chronicisation de la douleur.

Le risque de mobilisation du cathéter (5 à 25 %) réduit potentiellement le bénéfice analgésique. Le cathéter fémoral, par le bloc moteur induit et prolongé, peut favoriser les chutes, gêner la déambulation et la réhabilitation précoce après chirurgie prothétique du genou. Le cathéter interscalénique induit quant à lui une parésie diaphragmatique à prendre en compte en cas de pathologie respiratoire.

# Réactualisation de la recommandation sur la douleur postopératoire<sup>☆</sup>

Frédéric Aubrun<sup>1</sup>, Karine Nouette Gaulain<sup>2</sup>, Dominique Fletcher<sup>3</sup>, Anissa Belbachir<sup>4</sup>,  
Hélène Beloeil<sup>5</sup>, Michel Carles<sup>6</sup>, Philippe Cuvillon<sup>7</sup>, Christophe Dadure<sup>8</sup>, Gilles Lebuffe<sup>9</sup>,  
Emmanuel Marret<sup>10</sup>, Valéria Martinez<sup>3</sup>, Michel Olivier<sup>11</sup>, Nadia Sabourdin<sup>12</sup>, Paul Zetlaoui<sup>13</sup>,  
Société française d'anesthésie et de réanimation

**Recommandations formalisées d'experts**

## **Anesthésie locale et locorégionale postopératoire**

**Quelles indications et limites pour le cathétérisme périmerveux postopératoire ?**

Absence de recommandation.

# Réactualisation de la recommandation sur la douleur postopératoire<sup>☆</sup>

Frédéric Aubrun<sup>1</sup>, Karine Nouette Gaulain<sup>2</sup>, Dominique Fletcher<sup>3</sup>, Anissa Belbachir<sup>4</sup>,  
Hélène Beloeil<sup>5</sup>, Michel Carles<sup>6</sup>, Philippe Cuvillon<sup>7</sup>, Christophe Dadure<sup>8</sup>, Gilles Lebuffe<sup>9</sup>,  
Emmanuel Marret<sup>10</sup>, Valéria Martinez<sup>3</sup>, Michel Olivier<sup>11</sup>, Nadia Sabourdin<sup>12</sup>, Paul Zetlaoui<sup>13</sup>,  
Société française d'anesthésie et de réanimation

**Recommandations formalisées d'experts**

- ✓ Analgésie prolongée
- ✓ Epargne opioïde
- ✓ Réduction des effets indésirables
- ✓ Amélioration du sommeil
- ✓ Satisfaction des patients

# Réactualisation de la recommandation sur la douleur postopératoire<sup>☆</sup>

Frédéric Aubrun<sup>1</sup>, Karine Nouette Gaulain<sup>2</sup>, Dominique Fletcher<sup>3</sup>, Anissa Belbachir<sup>4</sup>,  
Hélène Beloeil<sup>5</sup>, Michel Carles<sup>6</sup>, Philippe Cuvillon<sup>7</sup>, Christophe Dadure<sup>8</sup>, Gilles Lebuffe<sup>9</sup>,  
Emmanuel Marret<sup>10</sup>, Valéria Martinez<sup>3</sup>, Michel Olivier<sup>11</sup>, Nadia Sabourdin<sup>12</sup>, Paul Zetlaoui<sup>13</sup>,  
Société française d'anesthésie et de réanimation

## Recommandations formalisées d'experts

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# CATHETERS PERINERVEUX

---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# CATHETERS PERINERVEUX


---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

REGIONAL ANAESTHESIA

# Dislocation rates of perineural catheters: a volunteer study


D. Marhofer<sup>1,2</sup>, P. Marhofer<sup>3\*</sup>, L. Triffterer<sup>2</sup>, M. Leonhardt<sup>4</sup>, M. Weber<sup>1</sup> and M. Zeitlinger<sup>1</sup>



REGIONAL ANAESTHESIA

# Dislocation rates of perineural catheters: a volunteer study

D. Marhofer<sup>1,2</sup>, P. Marhofer<sup>3\*</sup>, L. Triffterer<sup>2</sup>, M. Leonhardt<sup>4</sup>, M. Weber<sup>1</sup> and M. Zeitlinger<sup>1</sup>



REGIONAL ANAESTHESIA

## Dislocation rates of perineural catheters: a volunteer study

D. Marhofer<sup>1,2</sup>, P. Marhofer<sup>3\*</sup>, L. Triffterer<sup>2</sup>, M. Leonhardt<sup>4</sup>, M. Weber<sup>1</sup> and M. Zeitlinger<sup>1</sup>

### Standardized physical exercises and subsequent US investigations

The following standardized physical exercises were performed 60, 120, and 180 min after placement of both PNCs (all time points are relative to the placement and initial US confirmation of the catheters). Between the time points the volunteers had to lie down as still as possible.

- Twenty abductions of the arm up to 90°, 20 anteflexions of the arm up to 90°, and 20 retroflexions of the arm up to 30° (sitting position).
- Ten abductions of the leg with a 45° flexed hip up to 60°, 10 anteflexions of the leg up to 60° with parallel knee flexion (supine position).
- US investigation: administration of 5 ml saline through both catheters under direct US control (interscalene area and femoral nerve area) (supine position).

REGIONAL ANAESTHESIA


Dislocation rates of perineural catheters: a volunteer study

D. Marhofer<sup>1,2</sup>, P. Marhofer<sup>3\*</sup>, L. Triffterer<sup>2</sup>, M. Leonhardt<sup>4</sup>, M. Weber<sup>1</sup> and M. Zeitlinger<sup>1</sup>




# The Effect of Fixation Technique on Continuous Interscalene Nerve Block Catheter Success: A Randomized, Double-Blind Trial



David B. Auyong, MD,\* David Asher Cantor, MD,\* Cynthia Green, PhD,† and Neil A. Hanson, MD\*



# Intrapartum epidural fixation methods: a randomised controlled trial of three different epidural catheter securement devices\*



P. M. Odor,<sup>1</sup> S. Bampoe,<sup>1</sup> J. Hayward,<sup>1</sup> I. Chis Ster<sup>2</sup> and E. Evans<sup>3</sup>





## An analysis of 1505 consecutive patients receiving continuous interscalene analgesia at home: a multicentre prospective safety study

M. J. Fredrickson,<sup>1,2</sup> P. Leightley,<sup>2</sup> A. Wong,<sup>2</sup> M. Chaddock,<sup>2</sup> A. Abeysekera<sup>2</sup> and C. Frampton<sup>3</sup>

**Table 3** Early outcomes of patients included in the study (n = 1458). Values are number (proportion) or median (IQR [range]).

Catheter dislodgement	22 (1.5%)
Postoperative day of catheter removal	
1	6 (0.4%)
2	100 (7%)
3	763 (53%)
4	437 (30%)
> 4	137 (9%)



## An analysis of 1505 consecutive patients receiving continuous interscalene analgesia at home: a multicentre prospective safety study

M. J. Fredrickson,<sup>1,2</sup> P. Leightley,<sup>2</sup> A. Wong,<sup>2</sup> M. Chaddock,<sup>2</sup> A. Abeysekera<sup>2</sup> and C. Frampton<sup>3</sup>

**Table 3** Early outcomes of patients included in the study (n = 1458). Values are number (proportion) or median (IQR [range]).

Catheter dislodgement	22 (1.5%)
Postoperative day of catheter removal	
1	6 (0.4%)
2	100 (7%)
3	763 (53%)
4	437 (30%)
> 4	137 (9%)

# CATHETERS PERINERVEUX

---


- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# CATHETERS PERINERVEUX


---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?


# Electrophysiological Study of Femoral Nerve Function After a Continuous Femoral Nerve Block for Anterior Cruciate Ligament Reconstruction



# Electrophysiological Study of Femoral Nerve Function After a Continuous Femoral Nerve Block for Anterior Cruciate Ligament Reconstruction




# Electrophysiological Study of Femoral Nerve Function After a Continuous Femoral Nerve Block for Anterior Cruciate Ligament Reconstruction




# Time Course of Quad Strength, Area and Activation after Knee Arthroplasty and Strength Training

SC Petterson<sup>1</sup>, P Barrance<sup>2</sup>, AR Marmon<sup>1</sup>, T Handling<sup>1</sup>, TS Buchanan<sup>3</sup>, and L Snyder-Mackler<sup>1</sup>




# Electrophysiological Study of Femoral Nerve Function After a Continuous Femoral Nerve Block for Anterior Cruciate Ligament Reconstruction



## Functional Outcomes<sup>a</sup>

	CFNB Group	IV PCA Group	<i>P</i> Value
Quadriceps muscle strength (1-5), median (IQR)			
POD 1	2 (2-3)	3 (2-3)	.05
POD 2	3 (2-3)	3 (3-3)	.22
Active flexion, deg			
POD 1	67 ± 20	57 ± 18	.06
POD 2	75 ± 15	72 ± 15	.49
Distance walked, m			
POD 1	47 ± 29	55 ± 37	.42
POD 2	76 ± 35	65 ± 30	.32


# Electrophysiological Study of Femoral Nerve Function After a Continuous Femoral Nerve Block for Anterior Cruciate Ligament Reconstruction



## Functional Outcomes<sup>a</sup>

	CFNB Group	IV PCA Group	<i>P</i> Value
Quadriceps muscle strength (1-5), median (IQR)			
POD 1	2 (2-3)	3 (2-3)	.05
POD 2	3 (2-3)	3 (3-3)	.22
Active flexion, deg			
POD 1	67 ± 20	57 ± 18	.06
POD 2	75 ± 15	72 ± 15	.49
Distance walked, m			
POD 1	47 ± 29	55 ± 37	.42
POD 2	76 ± 35	65 ± 30	.32

# Electrophysiological Study of Femoral Nerve Function After a Continuous Femoral Nerve Block for Anterior Cruciate Ligament Reconstruction



## Functional Outcomes<sup>a</sup>

	CFNB Group	IV PCA Group	<i>P</i> Value
Quadriceps muscle strength (1-5), median (IQR)			
POD 1	2 (2-3)	3 (2-3)	.05
POD 2	3 (2-3)	3 (3-3)	.22
Active flexion, deg			
POD 1	67 ± 20	57 ± 18	.06
POD 2	75 ± 15	72 ± 15	.49
Distance walked, m			
POD 1	47 ± 29	55 ± 37	.42
POD 2	76 ± 35	65 ± 30	.32

# The analgesic efficacy of local infiltration analgesia vs femoral nerve block after total knee arthroplasty: a systematic review and meta-analysis

E. Albrecht<sup>1,\*</sup>, O. Guyen<sup>2</sup>, A. Jacot-Guillarmod<sup>3</sup> and K. R. Kirkham<sup>4</sup>

Outcome	Reference	Group						Mean difference [95% CI]	I <sup>2</sup> (%)	P value
		Local infiltration analgesia			Femoral nerve block					
		Mean or n	SD	N	Mean or n	SD	N			
Quadriceps muscle strength (pounds)										
Postoperative day one	Ng 2012 <sup>45</sup>	2.0	0.4	16	2.2	0.2	16	-0.1 [-0.4, 0.1]	-	0.19
Postoperative day two	Ng 2012 <sup>45</sup>	2.6	0.5	16	2.7	0.2	16	-0.2 [-0.4, 0.1]	-	0.23
Postoperative day three	Ng 2012 <sup>45</sup>	2.8	0.2	16	2.8	0.2	16	0.0 [-0.2, 0.2]	-	1.00

# The analgesic efficacy of local infiltration analgesia vs femoral nerve block after total knee arthroplasty: a systematic review and meta-analysis

E. Albrecht<sup>1,\*</sup>, O. Guyen<sup>2</sup>, A. Jacot-Guillarmod<sup>3</sup> and K. R. Kirkham<sup>4</sup>

Outcome	Reference	Group						Mean difference [95% CI]	I <sup>2</sup> (%)	P value
		Local infiltration analgesia			Femoral nerve block					
		Mean or n	SD	N	Mean or n	SD	N			
Quadriceps muscle strength (pounds)										
Postoperative day one	Ng 2012 <sup>45</sup>	2.0	0.4	16	2.2	0.2	16	-0.1 [-0.4, 0.1]	-	0.19
Postoperative day two	Ng 2012 <sup>45</sup>	2.6	0.5	16	2.7	0.2	16	-0.2 [-0.4, 0.1]	-	0.23
Postoperative day three	Ng 2012 <sup>45</sup>	2.8	0.2	16	2.8	0.2	16	0.0 [-0.2, 0.2]	-	1.00

# CATHETERS PERINERVEUX

---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# CATHETERS PERINERVEUX

---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# Inpatient Falls after Total Knee Arthroplasty

## *The Role of Anesthesia Type and Peripheral Nerve Blocks*

Stavros G. Memtsoudis, M.D., Ph.D., F.C.C.P., Thomas Danninger, M.D.,

**Table 1.** Patient Demographics, Healthcare-related, Procedure-related, and Comorbidity Measure Variables for Patients Subgrouped by Fall/No Fall

	Fall (N = 3,042)		No Fall (N = 188,528)		P Value†
	N*	%*	N*	%*	
Procedure related					
Type of anesthesia					
Neuraxial	280	9.2	20,705	11.0	0.002
General	2,393	78.7	143,493	76.1	
Combined	369	12.1	24,330	12.9	
Peripheral nerve block					
No block	2,666	87.6	165,669	87.9	0.693
Block	376	12.4	22,859	12.1	

# Inpatient Falls after Total Knee Arthroplasty

## *The Role of Anesthesia Type and Peripheral Nerve Blocks*


Stavros G. Memtsoudis, M.D., Ph.D., F.C.C.P., Thomas Danninger, M.D.,

**Table 1.** Patient Demographics, Healthcare-related, Procedure-related, and Comorbidity Measure Variables for Patients Subgrouped by Fall/No Fall

	Fall (N = 3,042)		No Fall (N = 188,528)		P Value†
	N*	%*	N*	%*	
Procedure related					
Type of anesthesia					
Neuraxial	280	9.2	20,705	11.0	0.002
General	2,393	78.7	143,493	76.1	
Combined	369	12.1	24,330	12.9	
Peripheral nerve block					
No block	2,666	87.6	165,669	87.9	0.693
Block	376	12.4	22,859	12.1	

# Falls and major orthopaedic surgery with peripheral nerve blockade: a systematic review and meta-analysis

R. L. Johnson<sup>1\*</sup>, S. L. Kopp<sup>1</sup>, J. R. Hebl<sup>1</sup>, P. J. Erwin<sup>2</sup> and C. B. Mantilla<sup>1</sup>



**Fig 2** Forest plot comparison of continuous lumbar plexus blockade vs non-continuous blockade or no block.

# The analgesic efficacy of local infiltration analgesia vs femoral nerve block after total knee arthroplasty: a systematic review and meta-analysis

E. Albrecht<sup>1,\*</sup>, O. Guyen<sup>2</sup>, A. Jacot-Guillarmod<sup>3</sup> and K. R. Kirkham<sup>4</sup>

Outcome	Reference	Group				Relative risk [95% CI]	I <sup>2</sup> (%)	P value
		Local infiltration analgesia		Femoral nerve block				
		n	N	n	N			
Neurologic events	Chaumeron 2013 <sup>14</sup>	1	29	1	30	0.7 [0.1, 4.0]	0	0.67
	Moghtadaei 2014 <sup>38</sup>	1	18	2	18			
	Uesugi 2014 <sup>40</sup>	0	100	0	100			
Cardiovascular events	Affas 2011 <sup>41</sup>	0	20	0	20	3.8 [0.4, 33.0]	0	0.23
	Carli 2010 <sup>13</sup>	1	20	0	20			
	Toftdahl 2007 <sup>47</sup>	2	40	0	37			
Falls	Chaumeron 2013 <sup>14</sup>	0	29	1	30	0.2 [0.0, 1.8]	0	0.16
	Spangehl 2014 <sup>46</sup>	0	81	3	79			

# The analgesic efficacy of local infiltration analgesia vs femoral nerve block after total knee arthroplasty: a systematic review and meta-analysis

E. Albrecht<sup>1,\*</sup>, O. Guyen<sup>2</sup>, A. Jacot-Guillarmod<sup>3</sup> and K. R. Kirkham<sup>4</sup>

Outcome	Reference	Group				Relative risk [95% CI]	I <sup>2</sup> (%)	P value
		Local infiltration analgesia		Femoral nerve block				
		n	N	n	N			
Neurologic events	Chaumeron 2013 <sup>14</sup>	1	29	1	30	0.7 [0.1, 4.0]	0	0.67
	Moghtadaei 2014 <sup>38</sup>	1	18	2	18			
	Uesugi 2014 <sup>40</sup>	0	100	0	100			
Cardiovascular events	Affas 2011 <sup>41</sup>	0	20	0	20	3.8 [0.4, 33.0]	0	0.23
	Carli 2010 <sup>13</sup>	1	20	0	20			
	Toftdahl 2007 <sup>47</sup>	2	40	0	37			
Falls	Chaumeron 2013 <sup>14</sup>	0	29	1	30	0.2 [0.0, 1.8]	0	0.16
	Spangehl 2014 <sup>46</sup>	0	81	3	79			

# The Risk of Falls After Total Knee Arthroplasty with the Use of a Femoral Nerve Block Versus an Adductor Canal Block: A Double-Blinded Randomized Controlled Study

Nabil M. Elkassabany, MD, MSCE,\* Sean Antosh, MD,\* Moustafa Ahmed, MD,\* Charles Nelson, MD,†

**Table 2. Physical Therapy Endpoint Assessment at 24 and 48 h**

	<b>ACB</b>	<b>FNB</b>	<b>P value</b>
Tinetti score at 24 h	15 (13–19)	14 (11–16)	0.13
Tinetti score at 48 h	22 (18–23)	18 (14–22)	0.17
Risk of falls at 24 h	21/31 (68%)	24/31 (77%)	0.7
Risk of falls at 48 h	7/31 (22%)	14/31 (45%)	0.06
TUG at 24 h (s)	65 (41–90)	75 (43–93)	0.7
TUG at 48 h (s)	43 (26–69)	45 (27–66)	0.9
Average ambulation distance at 24 h (feet)	20 (15–38)	15 (12.5–20)	0.08
Average ambulation distance at 48 h (feet)	60 (27.5–90)	47.5 (30–66.5)	0.5
MMT (24 h) extension	3 (3–3)	3 (2–3)	0.001*
MMT (48 h) extension	3 (3–3)	3 (3–3)	1

# CATHETERS PERINERVEUX

---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# CATHETERS PERINERVEUX

---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# Effectiveness of continuous versus single injection femoral nerve block for total knee arthroplasty: A double blinded, randomized trial

Varun Dixit<sup>a,\*,1</sup>, Samreen Fathima<sup>b</sup>, Stephen M. Walsh<sup>c,d</sup>, Alexandru Seviciu<sup>a</sup>,



	cFNB (n = 44)	sFNB (n = 41)	P value
Therapy delayed (%)	11% (5)	7% (3)	0.766
Unable to ambulate	9.2% (4)	2.4% (1)	–
Weakness/dizziness	2.3% (1)	4.8% (2)	
Distance-walked (m) (M ± SD)			
0 m at 1st session	16% (n = 7)	15% (n = 6)	–
At 1st PT session	109 ± 97	103 ± 84	–
At 2nd PT session	201 ± 180	210 ± 139	–
Assistive device			
Used at 1st session (%)	93% (40/41)	93% (37/38)	–
Knee immobilizer discharged at hospital	77.3% (34/44)	75.6% (31/41)	0.903
Time with knee immobilizer hours (M ± SD)	36 ± 12 (n = 38)	30 ± 11.7 (n = 38)	0.021*
Independent at 2nd session	43.2% (19/43)	65.9% (27/40)	0.036 <sup>¥</sup>
Hospital stay (M ± SD) (days)	2.2 ± 0.5	2.1 ± 0.4	0.517
Discharged to rehab (%) (n/N)	18.2% (8/44)	4.9% (2/41)	0.057

# Effectiveness of continuous versus single injection femoral nerve block for total knee arthroplasty: A double blinded, randomized trial

Varun Dixit<sup>a,\*,1</sup>, Samreen Fathima<sup>b</sup>, Stephen M. Walsh<sup>c,d</sup>, Alexandru Seviciu<sup>a</sup>,



	cFNB (n = 44)	sFNB (n = 41)	P value
Therapy delayed (%)	11% (5)	7% (3)	0.766
Unable to ambulate	9.2% (4)	2.4% (1)	–
Weakness/dizziness	2.3% (1)	4.8% (2)	
Distance-walked (m) (M ± SD)			
0 m at 1st session	16% (n = 7)	15% (n = 6)	–
At 1st PT session	109 ± 97	103 ± 84	–
At 2nd PT session	201 ± 180	210 ± 139	–
Assistive device			
Used at 1st session (%)	93% (40/41)	93% (37/38)	–
Knee immobilizer discharged at hospital	77.3% (34/44)	75.6% (31/41)	0.903
Time with knee immobilizer hours (M ± SD)	36 ± 12 (n = 38)	30 ± 11.7 (n = 38)	0.021*
Independent at 2nd session	43.2% (19/43)	65.9% (27/40)	0.036*
Hospital stay (M ± SD) (days)	2.2 ± 0.5	2.1 ± 0.4	0.517
Discharged to rehab (%) (n/N)	18.2% (8/44)	4.9% (2/41)	0.057

# Effectiveness of continuous versus single injection femoral nerve block for total knee arthroplasty: A double blinded, randomized trial

Varun Dixit<sup>a,\*,1</sup>, Samreen Fathima<sup>b</sup>, Stephen M. Walsh<sup>c,d</sup>, Alexandru Seviciu<sup>a</sup>,



	cFNB (n = 44)	sFNB (n = 41)	P value
Therapy delayed (%)	11% (5)	7% (3)	0.766
Unable to ambulate	9.2% (4)	2.4% (1)	–
Weakness/dizziness	2.3% (1)	4.8% (2)	
Distance-walked (m) (M ± SD)			
0 m at 1st session	16% (n = 7)	15% (n = 6)	–
At 1st PT session	109 ± 97	103 ± 84	–
At 2nd PT session	201 ± 180	210 ± 139	–
Assistive device			
Used at 1st session (%)	93% (40/41)	93% (37/38)	–
Knee immobilizer discharged at hospital	77.3% (34/44)	75.6% (31/41)	0.903
Time with knee immobilizer hours (M ± SD)	36 ± 12 (n = 38)	30 ± 11.7 (n = 38)	0.021*
Independent at 2nd session	43.2% (19/43)	65.9% (27/40)	0.036 <sup>¥</sup>
Hospital stay (M ± SD) (days)	2.2 ± 0.5	2.1 ± 0.4	0.517
Discharged to rehab (%) (n/N)	18.2% (8/44)	4.9% (2/41)	0.057

# Postoperative continuous adductor canal block for total knee arthroplasty improves pain and functional recovery: A randomized controlled clinical trial



Patrick Leung, MD<sup>a</sup>, David M. Dickerson, MD<sup>b</sup>, Sahitya K. Denduluri, MD<sup>a</sup>,

## Inpatient functional outcomes

	Control	cACB <sup>a</sup>	P-value
<i>Length of stay</i> (days)	2.42 (0.86)	2.67 (1.1)	0.28
ROM <sup>c</sup>			
POD 1 ROM (°)	51.4 (17)	40.6 (14)	0.006
POD 0–1 percent increase in ROM	35.5 (91)	22.4 (52)	0.58
POD 2 ROM (°)	71.3 (19)	62.5 (21)	0.09
POD 1–2 percent increase in ROM	35.9 (89)	61.1 (72)	0.24
<i>Ambulation distance</i>			
POD 1 ambulation distance (m)	13.8 (15.6)	17.6 (21)	0.39
POD 0–1 increase in ambulation distance (m)	12.6 (15.9)	15.7 (19.8)	0.5
POD 2 ambulation distance (m)	32.5 (26.2)	39.4 (31.8)	0.35
POD 1–2 increase in ambulation distance (m)	16.7 (20.8)	14.1 (33.6)	0.71

# Postoperative continuous adductor canal block for total knee arthroplasty improves pain and functional recovery: A randomized controlled clinical trial

Patrick Leung, MD<sup>a</sup>, David M. Dickerson, MD<sup>b</sup>, Sahitya K. Denduluri, MD<sup>a</sup>,

## Inpatient functional outcomes

	Control	cACB <sup>a</sup>	P-value
<i>Length of stay</i> (days)	2.42 (0.86)	2.67 (1.1)	0.28
ROM <sup>c</sup>			
POD 1 ROM (°)	51.4 (17)	40.6 (14)	0.006
POD 0–1 percent increase in ROM	35.5 (91)	22.4 (52)	0.58
POD 2 ROM (°)	71.3 (19)	62.5 (21)	0.09
POD 1–2 percent increase in ROM	35.9 (89)	61.1 (72)	0.24
<i>Ambulation distance</i>			
POD 1 ambulation distance (m)	13.8 (15.6)	17.6 (21)	0.39
POD 0–1 increase in ambulation distance (m)	12.6 (15.9)	15.7 (19.8)	0.5
POD 2 ambulation distance (m)	32.5 (26.2)	39.4 (31.8)	0.35
POD 1–2 increase in ambulation distance (m)	16.7 (20.8)	14.1 (33.6)	0.71


# Postoperative continuous adductor canal block for total knee arthroplasty improves pain and functional recovery: A randomized controlled clinical trial

Patrick Leung, MD<sup>a</sup>, David M. Dickerson, MD<sup>b</sup>, Sahitya K. Denduluri, MD<sup>a</sup>,

## Knee range of motion at 3 and 6 weeks follow-up

	Control	cACB <sup>a</sup>	P-value
Preoperative ROM <sup>b</sup> (°)	102 (18)	92.7 (26)	0.10
ROM <sup>b</sup> At 3 weeks (°)	98.2 (11.5)	94.3 (13.0)	0.21
ROM <sup>b</sup> At 6 weeks (°)	109 (14.0)	105 (10.2)	0.24
Paired outcome: Baseline → 3-week ROM <sup>b</sup> improvement	$P = 0.34$	$P = 0.76$	–
Paired outcome: Baseline → 6-week ROM <sup>b</sup> improvement	$P = 0.06$	$P = 0.01$	–

# Postoperative continuous adductor canal block for total knee arthroplasty improves pain and functional recovery: A randomized controlled clinical trial



Patrick Leung, MD<sup>a</sup>, David M. Dickerson, MD<sup>b</sup>, Sahitya K. Denduluri, MD<sup>a</sup>,

WOMAC scores at 3 and 6 weeks follow-up

	Control	cACB <sup>a</sup>	P-value	Mean difference (CI <sup>b</sup> )
Preoperative WOMAC <sup>c</sup> score (n = 70)	50.1 (13)	53.8 (20)	0.37	–
WOMAC <sup>c</sup> score at 3 weeks	37.8 (13)	29.1 (15)	0.04	–8.72 (–17.3 to –0.11)
WOMAC <sup>c</sup> score at 6 weeks	32.9 (14)	27.9 (17)	0.4	–
Paired outcome: Baseline → 3-week WOMAC <sup>c</sup> score improvement	P = 0.002	P = 0.0001	–	–
Paired outcome: Baseline → 6-week WOMAC <sup>c</sup> score improvement	P = 0.0002	P = 0.0002	–	–

# CATHETERS PERINERVEUX

---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# CATHETERS PERINERVEUX


---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# Patient-controlled Interscalene Analgesia with Ropivacaine 0.2% Versus Patient-controlled Intravenous Analgesia after Major Shoulder Surgery


## Effects on Diaphragmatic and Respiratory Function

Alain Borgeat, M.D.,\* Henry Perschak, M.D.,† Patricia Bird, M.D.,‡ Juerg Hodler, M.D.,§ Christian Gerber, M.D.||



**PCIA**

--▲-- forced respiration  
—■— tidal respiration



**PCIVA**

--▲-- forced respiration  
—■— tidal respiration

**(B)**

# *Patient-controlled Interscalene Analgesia with Ropivacaine 0.2% Versus Patient-controlled Intravenous Analgesia after Major Shoulder Surgery*

## *Effects on Diaphragmatic and Respiratory Function*

Alain Borgeat, M.D.,\* Henry Perschak, M.D.,† Patricia Bird, M.D.,‡ Juerg Hodler, M.D.,§ Christian Gerber, M.D.||


**Table 2. Mean Spirometry Values in the PCIA and PCIVA Groups**

	PCIA Group	PCIVA Group
VC (l)		
0	3.7 ± 1.5	3.8 ± 1.7
1	2.4 ± 1.1	2.6 ± 1.4
2	2.6 ± 1.2	3.1 ± 1.6
3	2.9 ± 1.7	3.3 ± 1.6
FEV <sub>1</sub> (l)		
0	2.9 ± 1.0	3.0 ± 1.2
1	1.8 ± 0.9	2.1 ± 1.1
2	2.0 ± 0.9	2.4 ± 1.1
3	2.3 ± 1.2	2.6 ± 1.2
PEFR (l/min)		
0	7.0 ± 2.7	6.7 ± 2.9
1	4.6 ± 2.1	5.1 ± 2.4
2	5.1 ± 2.3	5.7 ± 2.5
3	5.6 ± 2.5	6.0 ± 2.4

**NS**


# Comparison of Anterior Suprascapular, Supraclavicular, and Interscalene Nerve Block Approaches for Major Outpatient Arthroscopic Shoulder Surgery

David B. Auyong, M.D., Neil A. Hanson, M.D., Raymond S. Joseph, M.D., Brian E. Schmidt, M.D.,



# Comparison of Anterior Suprascapular, Supraclavicular, and Interscalene Nerve Block Approaches for Major Outpatient Arthroscopic Shoulder Surgery

David B. Auyong, M.D., Neil A. Hanson, M.D., Raymond S. Joseph, M.D., Brian E. Schmidt, M.D.,



# CATHETERS PERINERVEUX

---

- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?

# CATHETERS PERINERVEUX

---


- Mobilisation de cathéter ?
- Bloc moteur ?
- Chutes ?
- Réhabilitation ?
- Parésie phrénique ?
- Bonus Track: Ils sont toxiques !

# Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers†

K. KNUDSEN, M. BECKMAN SUURKÜLA, S. BLOMBERG, J. SJÖVALL AND N. EDVARDSSON



Subject No.	Age (yr)	Weight (kg)	Height (cm)	Dose	
				Rop. (mg)	Bup. (mg)
1	23	83	194	90	70
2	28	85	191	90	125
3	33	91	182	120	90
4	29	85	185	110	95
5	27	90	184	130	165
6	29	82	186	160	120
7	29	75	177	150	135
8	28	82	184	85	70
9	29	81	183	150	85
10	28	90	190	70	100
11	27	81	187	120	100
12	28	74	176	105	85
Mean	28	83	185	115	103
SD	2.2	5.4	5.3	29	30
Min.	23	74	176	85	70
Max.	33	91	194	160	165




# Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers†


K. KNUDSEN, M. BECKMAN SUURKÜLA, S. BLOMBERG, J. SJÖVALL AND N. EDVARDSSON



Dose

Subject No.	Age (yr)	Weight (kg)	Height (cm)	Rop. (mg)	Bup. (mg)
1	23	83	194	90	70
2	28	85	191	90	125
3	33	91	182	120	90
4	29	85	185	110	95
5	27	90	184	130	165
6	29	82	186	160	120
7	29	75	177	150	135
8	28	82	184	85	70
9	29	81	183	150	85
10	28	90	190	70	100
11	27	81	187	120	100
12	28	74	176	105	85
Mean	28	83	185	115	103
SD	2.2	5.4	5.3	29	30
Min.	23	74	176	85	70
Max.	33	91	194	160	165






$5 \times t_{1/2} = 9h$

$t_{1/2} = 1.8h$


CI = 15 L/h



# Neurotoxicity of Adjuvants used in Perineural Anesthesia and Analgesia in Comparison with Ropivacaine

BMJ Journals


Brian A. Williams, MD, MBA<sup>\*,†,‡</sup>, Karen A. Hough, AS, CVT, RLAT<sup>\*,†</sup>, Becky Y. K. Tsui, MPH,



# Neurotoxicity of Adjuvants used in Perineural Anesthesia and Analgesia in Comparison with Ropivacaine


BMJ Journals

Brian A. Williams, MD, MBA<sup>\*,†,‡</sup>, Karen A. Hough, AS, CVT, RLAT<sup>\*,†</sup>, Becky Y. K. Tsui, MPH,




# Local Anesthetic Schwann Cell Toxicity is Time and Concentration-Dependent

Sufang Yang, MD




# The role of regional anaesthesia and multimodal analgesia in the prevention of chronic postoperative pain: a narrative review

Y.-Y.K. Chen<sup>1</sup>, K.A. Boden<sup>2</sup>, K.L. Schreiber<sup>3</sup> [Assistant Professor]



# The role of regional anaesthesia and multimodal analgesia in the prevention of chronic postoperative pain: a narrative review

Y.-Y.K. Chen<sup>1</sup>, K.A. Boden<sup>2</sup>, K.L. Schreiber<sup>3</sup> [Assistant Professor]



# CONCLUSION

- Cathéter périmerveux = toujours le gold standard
- Identifier les patients à risque de douleur mal contrôlée
  - Femme; âge jeune; surpoids
  - Profil anxieux; attentes élevées
  - Comportement inadapté à la douleur
  - Atteinte fonctionnelle préopératoire importante
  - Qualité de vie dégradée